Glassman P, Chen Y, Balthasar J
J Pharmacokinet Pharmacodyn. 2015; 42(5):527-40.
PMID: 26364301
DOI: 10.1007/s10928-015-9444-y.
Valecha N, Gupta U, Mehta V
Eur J Drug Metab Pharmacokinet. 1993; 18(3):251-3.
PMID: 8149942
DOI: 10.1007/BF03188804.
Jerling M, Alvan G
Eur J Clin Pharmacol. 1994; 46(1):67-70.
PMID: 8005189
DOI: 10.1007/BF00195918.
Laznicek M, Laznickova A
Eur J Drug Metab Pharmacokinet. 1994; 19(1):21-6.
PMID: 7957447
DOI: 10.1007/BF03188818.
Mandelli M, Tognoni G
Clin Pharmacokinet. 1980; 5(5):424-40.
PMID: 7408367
DOI: 10.2165/00003088-198005050-00002.
The unsteady model. An alternative approach to nonlinear pharmacokinetics.
Smith M, Smith T
Eur J Clin Pharmacol. 1981; 20(5):387-98.
PMID: 7286050
DOI: 10.1007/BF00615410.
On the identification of Michaelis-Menten elimination parameters from a single dose-response curve.
Godfrey K, Fitch W
J Pharmacokinet Biopharm. 1984; 12(2):193-221.
PMID: 6491901
DOI: 10.1007/BF01059278.
Bioavailability limits.
Levy G
Can Med Assoc J. 1972; 107(8):722 passim.
PMID: 4638843
PMC: 1940991.
A modern view of pharmacokinetics.
Wagner J
J Pharmacokinet Biopharm. 1973; 1(5):363-401.
PMID: 4599379
DOI: 10.1007/BF01059664.
The pharmacokinetics of neostigmine and 3-hydroxyphenyltrimethyl- ammonium in the rat: dose-dependent effects after portal vein administration.
Barber H, Bourne G
Br J Pharmacol. 1974; 52(4):567-77.
PMID: 4455331
PMC: 1776893.
DOI: 10.1111/j.1476-5381.1974.tb09725.x.
Clinical pharmacokinetics of the salicylates.
Needs C, Brooks P
Clin Pharmacokinet. 1985; 10(2):164-77.
PMID: 3888490
DOI: 10.2165/00003088-198510020-00004.
Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics.
Brosen K, Gram L, Klysner R, Bech P
Eur J Clin Pharmacol. 1986; 30(1):43-9.
PMID: 3709631
DOI: 10.1007/BF00614194.
Chemical carcinogens: a review of the science and its associated principles. U.S. Interagency Staff Group on Carcinogens.
Environ Health Perspect. 1986; 67:201-82.
PMID: 3530737
PMC: 1474412.
DOI: 10.1289/ehp.67-1474412.
Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
Brosen K
Clin Pharmacokinet. 1990; 18(3):220-39.
PMID: 2182263
DOI: 10.2165/00003088-199018030-00004.
Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose.
Shen J, Wanwimolruk S, Purves R, McQueen E, Roberts M
J Pharmacokinet Biopharm. 1991; 19(5):575-95.
PMID: 1783992
DOI: 10.1007/BF01062964.
Area-dose relationships in nonlinear models.
Chau N
J Pharmacokinet Biopharm. 1976; 4(6):537-51.
PMID: 1011077
DOI: 10.1007/BF01064557.
Nonlinear assessment of phenytoin bioavailability.
Jusko W, Koup J, Alvan G
J Pharmacokinet Biopharm. 1976; 4(4):327-36.
PMID: 978395
DOI: 10.1007/BF01063122.
Importance of "first-pass elimination" for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol.
Alvan G, Lind M, Mellstrom B, von Bahr C
J Pharmacokinet Biopharm. 1977; 5(3):193-205.
PMID: 881641
DOI: 10.1007/BF01065395.
Time to reach steady state and prediction of steady-state concentrations for drugs obeying Michaelis-Menten elimination kinetics.
Wagner J
J Pharmacokinet Biopharm. 1978; 6(3):209-25.
PMID: 671227
DOI: 10.1007/BF01312263.
Steady-state plasma concentrations as a function of the absorption rate and dosing interval for drugs exhibiting concentration-dependent clearance: consequences for phenytoin therapy.
Sawchuk R, Rector T
J Pharmacokinet Biopharm. 1979; 7(6):543-55.
PMID: 529023
DOI: 10.1007/BF01061208.
